Abstract CT080: A phase I study of CPI-613 (devimistat) in combination with chemoradiation in patients with pancreatic ductal adenocarcinoma
Mandana Kamgar(Medical College of Wisconsin), William A. Hall(Medical College of Wisconsin), Sahar F. Bannoura(The Barbara Ann Karmanos Cancer Institute), Anikó Szabó(University of Wisconsin–Madison), Bradley A. Erickson(Medical College of Wisconsin), Asfar S. Azmi(The Barbara Ann Karmanos Cancer Institute), Husain Yar Khan(Wayne State University), Amro Aboukameel(The Barbara Ann Karmanos Cancer Institute), Susan Tsai(The Ohio State University Wexner Medical Center), Brian Y. Chung(Medical College of Wisconsin), Mohammed Najeeb Al Hallak(The Barbara Ann Karmanos Cancer Institute), Kathleen K. Christians(Medical College of Wisconsin), Douglas B. Evans(The University of Texas MD Anderson Cancer Center), Ben George(Medical College of Wisconsin), Yiwei Li(Ningxia Medical University), John M. Goldberg(Nomura Holdings (Japan)), Philip A. Philip(Wayne State University)
Cited by 3
Related Papers
Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy—3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology
|Radiotherapy and Oncology|2006|1.6k
Comprehensive Analysis of Hypermutation in Human Cancer
|Cell|2017|795
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Consensus Guidelines for Delineation of Clinical Target Volume for Intensity-Modulated Pelvic Radiotherapy for the Definitive Treatment of Cervix Cancer
|International Journal of Radiation Oncology*Biology*Physics|2010|458
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
|The Lancet. Gastroenterology & hepatology|2021|423